HER2 Peptide Vaccines for Breast Cancer: Research Update
Cancer Peptide Vaccines
94% 5-year DFS
The GP2 peptide vaccine achieved 94% 5-year disease-free survival in HER2-positive breast cancer patients who also received trastuzumab, compared to 89% in controls.
GLSI-100/GP2 Phase II Data
GLSI-100/GP2 Phase II Data
View as imageHER2 (human epidermal growth factor receptor 2) is overexpressed in approximately 20-25% of breast cancers, and even low levels of HER2 expression are present in 40-75% of all breast cancers. While monoclonal antibodies like trastuzumab (Herceptin) target HER2 on cancer cell surfaces, peptide vaccines take a fundamentally different approach: they train the patient's own immune system to recognize and destroy cells displaying HER2 fragments. Three HER2-derived peptide vaccines have reached clinical trials: E75 (nelipepimut-S/NeuVax), GP2, and AE37. Each targets a different part of the HER2 protein, uses a different immune activation pathway, and has generated a different clinical evidence profile. This article covers what personalized cancer vaccines look like when directed against a known, shared tumor antigen rather than a patient-specific neoantigen.
Key Takeaways
- E75 (nelipepimut-S) is a 9-amino acid HER2-derived peptide that binds HLA-A2/A3 molecules and activates CD8+ cytotoxic T cells; phase II showed 89.7% vs 80.2% 5-year DFS, but the phase III PRESENT trial was stopped for futility
- GP2 is a HER2 transmembrane domain peptide that activates CD8+ T cells through HLA-A2; in HER2-positive patients receiving trastuzumab, GP2 vaccination produced 94% vs 89% 5-year DFS, and the phase III FLAMINGO-01 trial (GLSI-100) is ongoing
- AE37 is a modified HER2 peptide (Ii-Key hybrid) that activates CD4+ helper T cells rather than CD8+ killer T cells, showing particular benefit in triple-negative breast cancer patients
- All three vaccines target the adjuvant setting (after primary treatment, to prevent recurrence) rather than treating active metastatic disease
- The phase III failure of NeuVax illustrates a core challenge of peptide vaccines: generating sufficient immune responses in the clinical setting despite promising immunogenicity data in earlier trials
- Cancer vaccine formulation significantly affects whether peptide vaccines synergize with or are inhibited by checkpoint blockade therapy (Hailemichael et al., 2018)
How HER2 Peptide Vaccines Work
HER2 peptide vaccines present short fragments (epitopes) of the HER2 protein to the immune system, priming T cells to recognize and kill cells that display those fragments. The mechanism differs from antibody-based therapies like trastuzumab, which physically block HER2 signaling on cell surfaces.
The peptide vaccine approach has three steps:
Peptide injection with adjuvant: A synthetic HER2 peptide fragment is injected intradermally, typically with granulocyte-macrophage colony-stimulating factor (GM-CSF) as an immunoadjuvant. GM-CSF recruits and activates dendritic cells at the injection site.
Antigen presentation: Dendritic cells take up the peptide, process it, and present it on HLA (human leukocyte antigen) molecules to T cells in lymph nodes. This is where HLA restriction becomes a critical limitation. Each peptide binds only specific HLA alleles. E75 and GP2 bind HLA-A2 (present in approximately 40-50% of the population) and HLA-A3. Patients without matching HLA types cannot mount an immune response to the vaccine.
T cell activation: Activated T cells proliferate, circulate through the body, and destroy cells presenting HER2 epitopes on their surface. CD8+ cytotoxic T cells (activated by E75 and GP2) directly kill cancer cells. CD4+ helper T cells (activated by AE37) coordinate broader immune responses and support long-term immunological memory.[1]
E75 (Nelipepimut-S/NeuVax): Promise and Phase III Failure
E75 (HER2/neu 369-377) is a 9-amino acid peptide derived from the extracellular domain of HER2. It binds HLA-A2 and HLA-A3, activating CD8+ cytotoxic T lymphocytes that target HER2-expressing cells.
Phase II results
The initial clinical development of E75, led by the US Military Cancer Institute, generated enthusiasm. In phase I/II trials (studies I-01 and I-02), node-positive breast cancer patients who were disease-free after standard therapy received E75 plus GM-CSF or GM-CSF alone. At 60 months of follow-up, 5-year disease-free survival was 89.7% in vaccinated patients versus 80.2% in controls, representing a 48% reduction in relative risk of recurrence. The vaccine was well-tolerated, with primary side effects being injection-site reactions and mild systemic symptoms.
The immunological data was equally encouraging. Vaccinated patients developed measurable HER2-specific CD8+ T cell responses, and the magnitude of immune response correlated with clinical benefit. Booster doses maintained immunity over time.
Phase III PRESENT trial
Based on these results, the randomized, double-blind, placebo-controlled phase III PRESENT trial (NCT01479244) enrolled 758 HLA-A2/A3-positive women with early-stage, node-positive breast cancer and low-to-intermediate HER2 expression (IHC 1+ or 2+). Patients received either nelipepimut-S plus GM-CSF or placebo plus GM-CSF.
The trial was stopped at interim analysis for futility. There was no significant difference in disease-free survival between vaccine and placebo groups. The reasons for the phase II to phase III translation failure are instructive:
Population selection: The phase III enrolled low-to-intermediate HER2 expressors, while the strongest phase II signals were in higher HER2 expression groups. The target population may not have had sufficient HER2 epitope density on residual cancer cells.
Immune response magnitude: Clinical-grade vaccine production at phase III scale may have produced different immunogenicity than smaller-batch manufacturing.
Statistical design: The trial may have been underpowered to detect the modest effect size achievable with a single-peptide vaccine in a favorable-prognosis population.
DCIS trial
A separate phase II trial evaluated nelipepimut-S in women with ductal carcinoma in situ (DCIS), a pre-invasive breast cancer. The rationale was that DCIS represents an earlier disease stage where immune surveillance might be more effective. Results from this trial (published 2024) provided additional immunological data but did not establish a definitive clinical benefit.[2]
GP2 (GLSI-100): The Current Frontrunner
GP2 (HER2/neu 654-662) is a 9-amino acid peptide derived from the transmembrane domain of HER2. Like E75, it binds HLA-A2 and activates CD8+ cytotoxic T cells, but it targets a different region of the protein.
Phase II results
In phase II adjuvant trials, GP2 plus GM-CSF was evaluated in breast cancer patients who had completed standard therapy. The intention-to-treat analysis at 34 months median follow-up showed 88% estimated 5-year disease-free survival in vaccinated patients versus 81% in GM-CSF-only controls.
The critical finding emerged in the HER2-positive subgroup (all of whom had received trastuzumab): disease-free survival was 94% in vaccinated patients versus 89% in controls. Zero recurrences occurred in the GP2-vaccinated, HER2-positive subgroup during the primary analysis period. This suggests GP2 may provide additional protection beyond trastuzumab in HER2-positive disease.
Phase III FLAMINGO-01
Based on these results, the FLAMINGO-01 trial (NCT05232916) is evaluating GLSI-100 (GP2 + GM-CSF) in a phase III setting. This trial enrolled HER2-positive breast cancer patients and represents the most advanced current effort to bring a HER2 peptide vaccine to approval. The FDA granted fast-track designation to GLSI-100 for prevention of recurrence in HER2-positive breast cancer.
The trial design incorporates lessons from the NeuVax PRESENT failure: it focuses on HER2-positive (rather than low-expressing) patients where the biological rationale is strongest, and all patients receive trastuzumab, testing whether the vaccine adds benefit to the current standard of care.
AE37: The Helper T Cell Approach
AE37 (Ii-Key/HER2 776-790) takes a fundamentally different immunological approach. Instead of activating CD8+ killer T cells directly, AE37 uses a modified HER2 peptide (linked to the Ii-Key peptide LRMK) that binds HLA class II molecules and activates CD4+ helper T cells.[3]
CD4+ T cell activation is important because helper T cells coordinate the broader adaptive immune response. They help activate and sustain CD8+ killer T cells, support B cell antibody production, and establish long-term immunological memory. A vaccine that activates both CD4+ (via AE37) and CD8+ (via E75 or GP2) pathways could theoretically produce a more durable and complete anti-tumor immune response.
Clinical findings
Phase II results showed AE37 was safe and immunogenic. The most interesting clinical signal emerged in subgroup analyses:
Triple-negative breast cancer (TNBC): AE37 showed a trend toward disease-free survival benefit specifically in TNBC patients. This was unexpected because TNBC is defined by lack of HER2 overexpression. However, low-level HER2 expression is present on most TNBC cells, and AE37's class II-mediated mechanism may be effective even at low antigen density.
Advanced stage disease: Patients with stage IIB or higher disease showed stronger benefit signals than early-stage patients.
These findings led to a phase II trial combining AE37 with pembrolizumab (anti-PD-1 checkpoint inhibitor) in metastatic TNBC (NCT04024800). The rationale is that AE37's CD4+ T cell activation could enhance the anti-tumor immune response when combined with checkpoint blockade, removing the immunosuppressive brakes that tumors use to evade immunity.
Why Vaccine Formulation Matters
Hailemichael et al. (2018) demonstrated that cancer vaccine formulation dramatically affects whether peptide vaccines synergize with or are inhibited by immune checkpoint blockade therapy. The study found that peptide vaccines formulated in depot-forming adjuvants (like incomplete Freund's adjuvant) trapped T cells at the injection site, preventing them from reaching tumors. When combined with checkpoint inhibitors, this formulation actually reduced anti-tumor efficacy.[4]
In contrast, peptide vaccines in non-depot formulations allowed activated T cells to traffic to tumors and synergized effectively with checkpoint blockade. This finding has significant implications for future HER2 peptide vaccine development, particularly as combination strategies with checkpoint inhibitors move into clinical testing.
The Neoantigen Position Effect
Capietto et al. (2020) contributed another insight relevant to all peptide cancer vaccines: the position of a mutation within a protein affects its immunogenicity. Mutations in certain structural positions are more likely to be presented on HLA molecules and recognized by T cells. This principle applies not only to neoantigen-based personalized vaccines but also to the selection and optimization of shared-antigen peptide vaccines like those targeting HER2.[5]
Next-Generation HER2 Peptide Vaccine Design
The field is evolving beyond single-peptide approaches. Firuzpour et al. (2025) used immunoinformatics and molecular dynamic simulation to design novel multi-peptide vaccines incorporating multiple HER2 epitopes that target both CD4+ and CD8+ T cells, with broader HLA coverage than any single-peptide vaccine.[6]
Multi-epitope peptide vaccines address several limitations of the current single-peptide approach:
Broader HLA coverage: By including epitopes that bind multiple HLA alleles, multi-peptide vaccines can be used in a larger proportion of patients.
Immune evasion resistance: Targeting multiple epitopes simultaneously reduces the chance that a tumor can escape by downregulating a single antigen.
Dual CD4+/CD8+ activation: Including both class I and class II epitopes produces the coordinated immune response that individual vaccines cannot achieve alone.
Alaei et al. (2025) reviewed the broader landscape of peptides in breast cancer therapy, noting that peptide-based approaches span from vaccines to peptide-drug conjugates to cell-penetrating peptides, with each modality addressing different aspects of breast cancer biology.[7]
Where the Field Stands
The current state of HER2 peptide vaccines in breast cancer can be summarized by three facts:
NeuVax (E75) failed phase III. Despite encouraging phase II data, the vaccine did not demonstrate efficacy in the low-to-intermediate HER2 population studied. This was the most expensive and ambitious peptide vaccine trial in breast cancer, and its failure tempered enthusiasm for the approach.
GP2 (GLSI-100) is in phase III. The FLAMINGO-01 trial represents the best remaining opportunity for a single-peptide HER2 vaccine to reach approval. Its design incorporates lessons from the NeuVax failure. The FDA fast-track designation reflects the unmet need for recurrence prevention in HER2-positive patients.
Combination approaches are expanding. AE37 plus checkpoint inhibitors, multi-epitope vaccines, and peptide vaccines combined with trastuzumab represent the next wave of clinical investigation. The consensus is moving toward combination immunotherapy rather than single-agent peptide vaccination.[8]
The broader context of peptide-based therapeutic cancer vaccines shows that this challenge is not unique to breast cancer. Peptide vaccines across tumor types have struggled to translate phase II immunogenicity signals into phase III survival benefits. The reasons are consistent: insufficient immune response magnitude, tumor immune evasion, suboptimal patient selection, and the immunosuppressive tumor microenvironment.
The Bottom Line
Three HER2 peptide vaccines (E75, GP2, AE37) have been tested in breast cancer clinical trials. E75 (NeuVax) showed promise in phase II but failed its phase III trial. GP2 (GLSI-100) is currently in phase III (FLAMINGO-01) after showing zero recurrences in HER2-positive patients on trastuzumab in phase II. AE37 showed unexpected benefit in triple-negative breast cancer and is being combined with checkpoint inhibitors. The field is moving toward multi-epitope vaccines and combination immunotherapy strategies. The central challenge remains generating sufficient anti-tumor immunity through peptide vaccination to produce measurable clinical benefit.